Reporting Gaps in mHealth Intervention Studies for Adults With Diabetes: Systematic Review.

JMIR Mhealth UhealthOct 1, 2026 (epub)
Clinical ResearchEndocrinologyOpen access

Xin Yue, Jiacheng Shen, Junke Peng et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the reporting completeness of 144 randomized controlled trials (RCTs) on mHealth interventions for adults with diabetes using the mERA checklist. The mean overall reporting score was 6.74 out of 16, highlighting significant gaps in critical areas such as interoperability and data security, which are essential for scalability and sustainability.

Key findings

  • The mean mERA reporting score was 6.74 out of 16, indicating substantial reporting deficiencies.
  • Only 8.3% of studies reported on interoperability, while 19.4% addressed data security.
  • Reporting completeness was significantly higher in studies published between 2016 and 2026 (P = .01).
  • Multicomponent interventions had better reporting completeness compared to single-component ones (P = .04).

Why it matters

Improving reporting standards in mHealth interventions is crucial for enhancing transparency and reproducibility, which can facilitate the effective translation of clinical research into scalable public health solutions for diabetes management.

Source

PubMed · PMID 42821868Free full text on PubMed Central

Published in JMIR Mhealth Uhealth. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.